Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Andrew Mehle · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $632,278 — ABSTRACT Influenza virus is a serious public health threat causing high levels of morbidity and mortality. The annual disease burden from influenza places a significant strain on our healthcare infrastructure and economy. This is despite many efforts to control disease with yearly vaccination, antiv…
DENNIS J. HARTIGAN-O'CONNOR · TENDEL THERAPIES INC. · 2024 · $300,083 — This project will test the ability of T follicular helper (Tfh) cell-targeting “genetic adjuvants” to improve immunogenicity of an advanced HIV envelope (Env) trimer. Eliciting neutralizing antibodies (nAb) against HIV will likely be required to create effective therapeutic vaccines that attenuate H…
Anna R. Smith · BOSTON UNIVERSITY MEDICAL CAMPUS · 2024 · $27,783 — ABSTRACT Alpha-1 antitrypsin deficiency (AATD) is a genetic disease most commonly caused by the Z point mutation in the SERPINA1 gene, resulting in misfolded Z-AAT protein polymerization in hepatocytes, cell death, and often cirrhosis. Replacement of ZZ with wild type MM hepatocytes via liver trans…
Mark Morris Davis · STANFORD UNIVERSITY · 2024 · $2,200,798 — PROJECT SUMMARY Influenza and SARS-CoV-2 are respiratory viruses that represent a continual threat to the health of many Americans, and will likely account for 100,000 deaths and many times that number of hospitalizations in the US alone each year. The available vaccines are inadequate, with the rec…
Cecilia Maria Leal · UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN · 2024 · $376,138 — PROJECT SUMMARY RNA therapeutics hold great promise for the treatment of a number of diseases significantly impacting human health, such as chronic infections, genetic disorders, certain cancers, and presently COVID-19. The leading RNA delivery vehicles approved by the FDA, as well as being consider…
Neil King · UNIVERSITY OF WASHINGTON · 2024 · $41,075,241 — PROJECT SUMMARY – OVERALL: MACHINE LEARNING-ENABLED DESIGN OF PROTOTYPE PATHOGEN VACCINES AND ANTIBODIES We propose a highly synergistic Center focused on developing end-to-end strategies for pandemic preparedness vaccine development for bunyaviruses and paramyxoviruses. Our Center brings together …
JOHN P MOORE · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $500,527 — Project Summary/Abstract Many potent and effective broadly neutralizing antibodies (bNAbs) directed to the HIV-1 envelope glycoprotein (Env) trimer have been studied mechanistically and structurally. Combined, their epitopes now cover most of the external surface of Env. Passive immunization with bN…
JAY PONDER · WASHINGTON UNIVERSITY · 2024 · $298,071 — PROJECT SUMMARY/ABSTRACT Nucleic acids (NAs) are the major information carrying molecules of life. The ability to use computation to model the structure, dynamic and interactions of DNA and RNA is a key adjunct to experimental study of these biomolecules. For example, pseudouridine-containing mRNA v…
Hannah Frizzell · ORLANCE, INC. · 2024 · $200,000 — PROJECT SUMMARY Orlance has developed a next-generation Gene Gun (MACH-1 GG) that efficiently delivers DNA and RNA into epidermal cells, leading to robust immune responses. Sequencing of tumors from individual patients has led to the identification of personalized neoantigens that could be targeted …
SCOTT W WONG · OREGON HEALTH & SCIENCE UNIVERSITY · 2024 · $1,212,634 — SUMMARY The overall goals of this U01 application are two-fold. First, to investigate two potential KSHV targets, one structural and one non-structural, to determine if these two targets are capable of protecting vaccinated animals from infection. And, the second, to compare two vaccine strategies t…
LLOYD M SMITH · UNIVERSITY OF WISCONSIN-MADISON · 2024 · $532,733 — Project Summary/Abstract The complexity of the HIV-1 transcriptome has been progressively revealed throughout recent decades using increasingly advanced RNA sequencing technologies. However, knowledge of the RNA primary sequence alone has not been sufficient to determine the importance or function o…
DANIEL G ANDERSON · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $726,005 — Many HIV vaccine candidates have failed clinical trials, as they were unable to elicit a potent and durable response to HIV viral challenge. Broadly neutralizing antibodies (bnAbs) have been identified in a number of HIV+ individuals with well-controlled viral levels, and these bnAbs target epitopes…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,393,751 — ABSTRACT OVERALL The main goal of our IPCAVD Program grant is to evaluate in humans self-amplifying mRNA (saRNA) vaccines that express two HIV-1 Env-derived protein immunogens that activate and initiate the maturation of VRC01-class B cell receptors (BCRs). The first immunogen, 426c.Mod.Core, was sp…
JOHN M MARIS · CHILDREN'S HOSP OF PHILADELPHIA · 2024 · $178,000 — PROJECT SUMMARY: U01 CA217959 Supplement Application This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 24-029. The parent Multiple Principal Investigator (MPI) Project proposal for the Pediatric Immunotherapy Network is focused on high-ris…
Erol Fikrig · L2 DIAGNOSTICS, LLC · 2024 · $299,969 — PROJECT SUMMARY Chikungunya is an arboviral disease transmitted to humans by infected mosquitoes, primarily the Aedes aegypti and Aedes albopictus species. The virus responsible for the disease is the chikungunya virus (CHIKV), a member of the Togaviridae family. First identified in Tanzania in 195…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $3,192,992 — Supplement request to DAIDS to Manufacture an mRNA/LNP encoding an HIV envelope designed to bind and stimulate multiple V2 Apex broadly neutralizing antibody B cell lineages Barton Haynes, CHAVD PI Thomas Denny, Investigator, manufacture team This request is to produce GMP an mRNA immunogen that enc…
Edward P Browne · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $415,427 — Project summary: Antiretroviral therapy (ART) has been successful at treating HIV infection and allowing people with HIV (PWH) to lead relatively normal lives. Nevertheless, a cure for HIV has remained elusive, and interruption of ART results in rapid viral rebound. HIV persists during therapy by it…
Yan Tang · TUFTS UNIVERSITY MEDFORD · 2024 · $659,481 — Abstract Lymphangioleiomyomatosis (LAM) is a genetic disorder caused by bi-allelic inactivating mutations in tumor suppressor genes TSC1 or TSC2, leading to progressive lung destruction and eventually the requirement for lung transplantation. Rapalogs, the only FDA-approved treatments for LAM, induc…
Paul Stephen Keim · NORTHERN ARIZONA UNIVERSITY · 2024 · $1,416,075 — OVERALL Section Title: Early in vivo expressed antigens and their role in virulence, immune response, and vaccines for coccidioidomycosis. SUMMARY Coccidioidomycosis, also known as Valley Fever (VF), is an important fungal disease caused by two different Coccidioides species that results in regional…
James D. Bryers · UNIVERSITY OF WASHINGTON · 2024 · $540,184 — While Staphylococcus aureus (SA) commonly asymptomatically colonizes the skin and nose of healthy humans, severe disease can result from infection of the blood, bone, skin, and lungs, as well as sites of catheters and prosthetic devices. With currently approved therapy, about one-third of patients d…